ATM mutation

Thanks @CCR_AACR for featuring our work on the clinico-genomic landscape of #ATM mutations in #NSCLC on this month’s cover! W/@ArielleElkrief @alessi_joao @XinAnnWang @DanaFarberNews @MSKCancerCenter @OncoAlert #LCSM Read more about this effort here: https://t.co/Fjp8oDYO3O (@BiagioRicciutMD)

New in @JNCI_Now from @MSKCancerCenter: ATM Germline-Mutated Gastroesophageal Junction Adenocarcinomas: Clinical Descriptors, Molecular Characteristics, and Potential Therapeutic Implications https://t.co/OhTIHtuxiQ ~6% of GEJ cancers harbor ATM mutations most all bi-allelic (@Aiims1742)

💫BRCA2 vs ATM mutations in metastatic prostate cancer: Divergent molecular features & clinical outcomes 💫 🔬 BRCA2 mutations linked to higher mutational burden & genomic instability 👨‍⚕️ Patients with BRCA2 mutations had better response to PARP inhibitors 💊 ATM mutations… https://t.co/fD1GFRle4v (@nataliagandur)

💫BRCA2 vs ATM mutations in metastatic prostate cancer: Divergent molecular features & clinical outcomes 💫 🔬 BRCA2 mutations linked to higher mutational burden & genomic instability 👨‍⚕️ Patients with BRCA2 mutations had better response to PARP inhibitors 💊 ATM mutations… https://t.co/0szeSSwAoc (@nataliagandur)

💫New study finds that metastatic #prostatecancer patients with #BRCA2 mutations have distinct molecular characteristics and better clinical outcomes compared to those with #ATM mutations. Important insights for precision medicine. https://t.co/47Kq07d3lV (@nataliagandur)

Congrats to @EAntonarakis @DrRanaMcKay @cancerassassin1 @EHeath4100 @charlesryanmd and other members of the @carisls POA on this recent @CCR_AACR paper on BRCA2 vs. ATM mutated #prostatecancer led by Dr. Hwang of @UMNCancer @neerajaiims @DrChoueiri https://t.co/Iw3AMYYgcB (@chadinabhan)

Feature in @urotoday, Metastatic Prostate Cancers with BRCA2 versus ATM Mutations Exhibit Divergent Molecular Features and Clinical Outcomes. https://t.co/CWSZAbinFF (@cancerassassin1)

Now online in @CCR_AACR: Metastatic Prostate Cancers with BRCA2 versus ATM Mutations Exhibit Divergent Molecular Features and Clinical Outcomes, Dr. Justin Hwang @EAntonarakis @UMNCancer and Caris Precision Oncology Alliance team. https://t.co/B8FYYrjSp3 (@cancerassassin1)

4/8 ATM mutant NSCLCs with complete loss of ATM expression by IHC were enriched in KRAS mutations, while TP53 alterations were more common in ATM mutant NSCLCs with intact ATM expression. (@BiagioMd)

2/8 We identified 562 deleterious ATM mutations in 9.7% (503/5172) of NSCLC samples. ATM mutations were associated with high TMB, increased PD-L1 expression and were enriched in KRAS, STK11, and ARID2 co-mutations. TP53 and EGFR mutations were enriched in ATM wild-type NSCLCs. (@BiagioMd)

Our multicenter study on the clinico-genomic and immunophenotypic landscape of #ATM mutations in #NSCLC is out in @CCR_AACR🚨. w/@ArielleElkrief, @alessi_joao, @XinAnnWang, @DrMarkAwad, @AdamJSchoenfeld & #MichaelCheng @DanaFarberNews @OncoAlert #LCSM https://t.co/vGlutSdZhE 1/8 (@BiagioMd)

5/8 In examining clinical outcomes to PD-(L)1 based therapies, there was no difference between patients with ATM mutant and ATM wild-type NSCLC, despite increased TMB/PD-L1 expression (though higher rate of KRAS/STK11 co-mutations) in the ATM mutant subset. (@BiagioMd)

That is so discouraging. I have an ATM mutation. My Dad died from pancreatic cancer. So did my dad’s dad. It’s crazy that we can’t make more progress through the generations. (Although I’ll be the first to have early regular screening, so there’s of course that!) (@amieroewastaken)

H.Pylori infection significantly increases the risk of gastric cancer in persons with inherited mutations in BRCA2, BRCA1 , ATM, and PALB2 compared to non-carriers. The good news is that eradicating H.Pylori is relatively easy and may help mitigate risk. https://t.co/weMai50Ja1 (@Ecastromarcos)

🎥 @AliSchram of @MSKCancerCenter talks on avelumab and talazoparib in BRCA1/2- or ATM-mutant solid tumors Watch: 👉https://t.co/dgHchGrda5👈 @myESMO #ESMOTAT23 (@VJOncology)

#Rucaparib or #Physician’s Choice in #Metastatic #ProstateCancer? This article shows #BRCA or ATM mutated Prostate Cancer patients respond better to this drug than not 👉https://t.co/ZDtyYOc9cy @NEJM (@davidhenrymd)

TRITON3 Rucaparib vs Physician’s Choice of Single-Agent Therapy in Metastatic Castration-Resistant Prostate Cancer With BRCA or ATM mutations in shows better results than chemotherapy or ARi #prostatecancer #CancerResearch #ASCOGU23 https://t.co/EJq9dO002i (@saadvikdr)

#GU23 #ASCOGU23 Not sure what you mean by "good evolution". Did you mean good response? I also had one ATM-mutant pt with a prolonged (36+ mo) response to PARPi. However, it's the exception, not rule. ATM mutation picked up on NGS is not a good biomarker for PARPi, it seems. (@young_whang)

T:👉Yeni faz 3 çalışması, metastatik prostat kanseri ve BRCA1, BRCA2 veya ATM mutasyonu olan hastalarda (kastrasyon tedavisine dirençli) rucaparib tedavisi, farklı bir tedavi alanlara göre daha uzun süre kanser ilerlemeden cevap verdi.* ✅ https://t.co/Nbuo6vlfkR (@ilyassahinMD)

TRITON3 met its primary endpoint of improving rPFS by the use of rucaparib vs physician's choice of therapy (Docetaxel or ARTi) in 2L BRCA-mutated (but not ATM) mCRPC. OS results are inmature. #GU24 #prostatecancer (@OncoLucus)

#GU23 #ASCOGU23 the paper from @NEJM https://t.co/F0itnVerwK In my experience, ATM mutated patient had good evolution with rucaparib. There must be more than meets the eye, not only mutated gene. (@duemed)

More data showing the benefits of #PARP inhibitors. #TRITON3 by @AlanBryce9 showing benefit to #rucaparib for 2nd line mCRPC. 75% had #BRCA mutations. Unsurprising no benefits for #ATM mutations. OS trending but not fully mature yet. #GU23 (@SFreedlandMD)

TRITON3–amazing data on PARPi in BRCA or ATM-mutated mCRPC. Positive for rPFS endpoint but look at dif between BRCA vs ATM. @AlanBryce9 #GU23 (@wandering_gu)

First study to show benefit of Parp inhibitor over chemotherapy in mCRPC with BRCA/ATM mutations. Looking forward to the oral presentation! (@RohanGarjeMD)

Today's WIPs: grad student Mia Hofstad from @gr8straj lab on molecular vulnerabilities in ATM mutant #prostatecancer and postdoc Yan Zhao from @joshuagruber lab on the VISTA immune checkpoint in triple-negative #breastcancer. Many implications for future treatments! (@UTSWGreenCenter)

Our second WIPs speaker today is Mia Hofstad, from @gr8straj lab, presenting on delineating molecular vulnerabilities of ATM mutant prostate cancers! (@UTSWCancerBio)

.@RutgersCancer / @RWJBarnabas Dr. Andrew Evens (@DrAEvens) & colleagues present “Mutations of ATM Confer a Risk of Inferior Survival in Patients with TP53-wild Type Mantle Cell Lymphoma” at #ASH22. @ASH_hematology @RWJMS https://t.co/jw096NPban (@RutgersCancer)

Watch: @Daniel_J_George discusses the use of niraparib for patients with metastatic castration-resistant prostate cancer harboring BRCA and ATM mutations. #pcsm https://t.co/FiI3xgD1xS (@OncLive)

Germline mutations in CHEK2, ATM, and BRCA2 are associated with #bladdercancer risk in newly published data from #UKBiobank @JianfengXuDrPH @prost8helf @Jtkearns @apglaser https://t.co/SpDWizVrfx (@NorthShoreUro)

The ATM cohort was a real disappointment. How to put that in context with the prostate cancer data as ATM mutations still have an OncoKb level of evidence 1 in this setting? https://t.co/7bA6PxWIwX @quimmateo @VivekSubbiah @BenWestphalen (@aftimosp)

Just in👉In mCRPC #ProstateCancer with ATM or BRCA2 mutations 👉improved outcomes when taxanes given first in ATM mutations, & vice versa with PARP inhibitors in BRCA2 mutations.👇Guidance for sequencing. Congrats @EAntonarakis Link: https://t.co/RJmsrz8ISL @OncoAlert @urotoday (@neerajaiims)

In @JAMAOnc: Next chapter of targeting BRCAness in solid cancers - combining PARP inh (Talazoparib) plus #Immunotherapy (Avelumab) across a spectrum of BRCA1/2 & ATM mutated cancers. Does it work? NOT a slam dunk Tumor type dependent muATM ❌ DDR! https://t.co/IlJOua0lGC (@Aiims1742)

Triton3 results of rucaparib vs physicians choice for BRCA1/2/ATM mutant CRPC from @AlanBryce9 @PCF_Science #PCFRetreat22 (@NimaSharifiMD)

👀 on that ATM mutation in colon cancer 💥 🎯 🧬 (@DrBonillaOnc)

👀 on that ATM mutation in colon cancer 💥 🎯 🧬 (@DrBonillaOnc)

More evidence that germline ATM mutations with low HRD scores are not candidates for PARP inhibitor monotherapy. No responses here in both #PancreaticCancer cases. (@Aiims1742)

Look at the clinical response of that ATM mutant angiosarcoma afyer 4 Gy x 2 🤩on the 4 th picture👍 And the 93 yo with ATM mut HNSCC treat led to just 44 Gy reached 100 yp age👍👍 #pleasantsurprises #believe #precisionmedicine Only at #RadRes2022 🥳 (@HenningWillers)

Rucaparib Meets rPFS End Point in BRCA/ATM-Mutated mCRPC https://t.co/mlhRXxu5KA via @onclive (@nachoduranm)

#TRITON3 phase 3 trial Of rucaparib (rubraca®) achieves primary endpoint in men with metastatic castration-resistant #ProstateCancer with BRCA or ATM mutations. @clovisoncology announces positive top-line data. #ReadNow details on UroToday > https://t.co/QE6D0GE7Ry @AlanBryce9 (@urotoday)

JUST IN: TRITON3 Phase 3 Trial Of Achieves Primary Endpoint In Men With Metastatic Castration-Resistant Prostate Cancer With BRCA/ATM Mutations https://t.co/6ESQTCjSan @DanaFarber_GU @OncoAlert @clovisoncology (@DrChoueiri)

TRITON3 Phase 3 Trial of Rubraca® (rucaparib) Achieves Primary Endpoint in Men with Metastatic Castration-Resistant Prostate Cancer with BRCA or ATM Mutations. Data submitted for presentation at the upcoming @PCF_Science Annual Meeting. https://t.co/jm3IMyOQ6I (@AtishChoudhury)

#TRITON3 Phase 3 Trial of #Rubraca® (rucaparib) Achieves Primary Endpoint in Men with Metastatic Castration-Resistant Prostate Cancer with BRCA or ATM Mutations (@a_nourallah)